standard care – Page 8 – Communicable Diseases Research

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

COVID-19를 가진 입원 환자를위한 회복기 혈장 : 개방형, 무작위 대조 시험

Randomized Controlled Trial

Published on 2021-09-092022-08-13
Journal: Nature Medicine [Category] MERS, SARS, 바이오마커, 변종, 임상, 진단, 치료법, 치료제,

Melatonin effects on sleep quality and outcomes of COVID‐19 patients: An open‐label, randomized, controlled trial

Randomized Controlled Trial

Published on 2021-09-082022-10-04
Journal: Journal of medical virology [Category] 임상,

[키워드] N‐acetyl‐5‐methoxytryptamine 2019‐nCoV Admission ARMS Blood oxygen saturation C‐reactive protein Characteristics clinical trial Combination control arm control group Controlled clinical trial coronavirus disease COVID‐19 COVID‐19 patient COVID‐19 Day Effect Effectiveness evaluate examined Hospitalized hospitalized COVID‐19 patients IMPROVE intensive care laboratory data Lymphocyte count melatonin Mortality no significant difference open‐label outcome oxygen saturation Patient patients peripheral capillary primary endpoint Randomized randomized, controlled trial receiving recruited SARS‐CoV‐2 secondary endpoint significantly significantly higher Sleep sleep quality standard care standard treatment Symptom Tablet Treatment treatment arm Treatment protocol Trial White blood cell
[DOI] 10.1002/jmv.27312 PMC 바로가기 [Article Type] Randomized Controlled Trial

Anakinra versus Baricitinib: Different Strategies for Patients Hospitalized with COVID-19 †

Article

Published on 2021-09-062022-10-30
Journal: Journal of Clinical Medicine [Category] COVID-19,

[키워드] addition Admission age Anakinra Analysis Baricitinib clinical outcomes Comorbidity Corticosteroids COVID-19 Cox regression model criteria Deceased died disease drug early interruption elevated lactate dehydrogenase evaluate the effect functional groups hospital immunomodulatory immunomodulatory therapy IMV in both group In-hospital death individual individuals inhibitor intensive care Invasive mechanical ventilation JAK inhibitor Laboratory Mortality occurred outcome oxygen Patient patients patients hospitalized patients treated Pneumonia propensity score matching radiological required severe COVID-19 standard care Strategy subject survival treated with COVID-19
[DOI] 10.3390/jcm10174019 PMC 바로가기 [Article Type] Article

Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial

중년의 중등도 증상 환자에서 아연과 시너지 효과를 나타내는 피하 이버멕틴의 항-COVID 특성: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-09-062022-09-10
Journal: Trials [Category] SARS, 임상,

[키워드] 30-Day mortality absence activities approved Arm blinded calculated Chest clinic clinical co-morbidities co-morbidity comparator coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 symptom Data collection death dissemination doctor ECMO Effectiveness element Endpoint enrolment Evidence evidence of excluded FIVE GRADE Grade 1 grade 3 Grade 5 group groups high resolution high resolution CT high-flow oxygen therapy Hospitalized HRCT Infection institutional review board Intention Invasive mechanical ventilation Ivermectin lung lobe mechanical ventilation morbidities nasal no evidence of noninvasive normal saline number objective outcome outcome assessor outcome assessors oxygen Oxygen therapy oxygen) Pakistan participant Patient patient recruitment patients with moderate PCR Physicians Placebo placebo group placebo-controlled positive pregnant women presence or absence primary care primary endpoints protocol radiological improvement randomisation randomised randomised controlled trial Randomized randomized clinical trial Randomly receive recorded Registered reported requiring supplemental oxygen Sample size SARS-CoV-2 SARS-CoV-2 clearance secondary endpoint seven-point scale severe respiratory syndrome severity Standard standard care status Study protocol Subcutaneous Ivermectin supplemental oxygen supplementary material symptomatic synergy Trial website Zinc
[DOI] 10.1186/s13063-021-05487-z PMC 바로가기 [Article Type] Letter

Recovery of a patient with severe COVID-19 by acupuncture and Chinese herbal medicine adjuvant to standard care

침술 및 중국 약초 보조제에 의한 심각한 코비드 -19 환자의 회복 표준 치료

Case Reports

Published on 2021-09-012022-08-31
Journal: Journal of integrative medicine [Category] MERS, 치료제,

[키워드] Absorption accelerate acupuncture addition adjuvant adjuvants breath breathing function C-reactive protein Case report Chest computed tomography Chinese Chinese herbal medicine Combination Computed tomography contagious coronavirus disease Coronavirus disease 2019 COVID-19 CRP decrease dosage effective therapy female heart rate herbal medicine Integrative therapy lesion life-threatening Lung infection lymphocyte MLR monocyte neutrophil NLR Older oxygen Patient peripheral oxygen saturation rescue seeking Severe case Severe case. severe cases severe COVID-19 Shortness of breath significantly standard care the patient therapy treated was increased Wuhan Wuhan, China
[DOI] 10.1016/j.joim.2021.06.001 PMC 바로가기 [Article Type] Case Reports

Interferon-alpha position in combating with COVID-19: A systematic review

COVID-19와의 싸움에서 인터페론-알파의 위치: 체계적인 검토

Review

Published on 2021-09-012022-09-11
Journal: Journal of medical virology [Category] 임상, 치료제,

Systemic corticosteroids for the treatment of COVID-19

COVID-19 치료를 위한 전신 코르티코스테로이드

Review

Published on 2021-08-162022-09-11
Journal: The Cochrane database of systematic reviews [Category] SARS, 임상,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome adjust adverse event adverse events age all-cause mortality analysed Analysis applicability approach arising Arm Asymptomatic asymptomatic infection baseline benefit caution CENTRAL certainty certainty of evidence change citation Cochrane COVID-19 Study Register Combination comparison Comparisons composite endpoint control group coronavirus disease coronavirus diseases Corticosteroid Corticosteroids COVID-19 Data collection death Descriptive statistics Dexamethasone Diagnosis direction disease disease severity dosage dosages dose doses doses of corticosteroids effective Effects eligible endpoints estimate Ethnicity evaluated Evidence excluded Factor FIVE Follow-up Gender heterogeneous high risk hospital-acquired infections hospitalised hyper-inflammation identify include index individual Inhaled inhaled corticosteroids inherent invasive Invasive mechanical ventilation invasive ventilation life limitation long-COVID majority median medRxiv methodology Methylprednisolone Middle East Middle East respiratory syndrome Mild Mild disease Mortality MOST New nine non-hospitalised occurred Other outcomes outcome outcomes Outpatient outpatients participant Participants Patient people with COVID-19 Placebo Population Quality Quality of life randomisation randomised randomised controlled trial Randomised controlled trials RCT RCTs reduce reduction in regimen reported Respiratory Support risk risk difference risk of bia risk ratio Safe Science Citation Index searched Selection Serious Adverse Events Severe acute respiratory syndrome standard care subgroup subgroups subsequent suspected diagnosis symptomatic symptomatic COVID-19 syndrome systematic review systemic systemic corticosteroid systemic corticosteroids the WHO therapy topical treat Treatment Trial Ventilation ventilator-free day Ventilator-free days Web of Science WHO ICTRP
[DOI] 10.1002/14651858.CD014963 PMC 바로가기 [Article Type] Review

Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic A Randomized Clinical Trial

Research

Published on 2021-08-132022-10-29
Journal: JAMA Network Open [Category] COVID-19, MERS, SARS,

[키워드] 1:1 95% CI adverse effects age benefit block randomization Brazil Burnout cannabidiol Care clinical COVID-19 COVID-19 pandemic Critical double-blind Effect effective Efficacy efficacy analysis elevated Elevation eligibility Emotional exhaustion enrolled Exhaustion Final finding full recovery Future Health Importance incidence Intervention inventory involved liver enzyme mean difference measure Mild Nurses objective Open-label participant Participants Patient patients with COVID-19 per day physical Physicians placebo-controlled clinical trial Point Primary outcome professional professionals Randomized randomized clinical trial receive receiving recruited reduced reducing reduction Registration Relevance reported researcher Result Safety School Serious Adverse Events service setting significantly Standard standard care survey Symptom Symptoms therapy Treatment treatment arm treatment group university were assessed women worker
[DOI] 10.1001/jamanetworkopen.2021.20603 PMC 바로가기 [Article Type] Research

Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial

Article

Published on 2021-08-122022-10-30
Journal: Journal of Clinical Medicine [Category] COVID-19,

[키워드] 95% confidence interval acute respiratory syndrome adverse event Analysis antiviral agent Antiviral agents assigned Ciclesonide clinical clinical trial conducted coronavirus coronavirus disease COVID-19 Diagnosis drug effective Efficacy enrolled evaluate evaluated groups High-flow nasal oxygen inhalation inhaler inhibit intravenous mechanical ventilation Mild-to-moderate multicenter nasopharyngeal viral load Negative conversion Open-label Patient per day Phase 2 polymerase chain primary endpoint progression Quantitative Randomized Randomly receive Registration Respiratory failure reverse transcription SARS-CoV-2 SARS-CoV-2 viral shedding significantly higher significantly lower standard care study enrollment symptom onset therapy treat Treatment
[DOI] 10.3390/jcm10163545 PMC 바로가기 [Article Type] Article

Therapeutic efficacy of macrolides in management of patients with mild COVID-19

가벼운 Covid-19 환자의 관리에서 마크로 라이드의 치료 효능

Randomized Controlled Trial

Published on 2021-08-112022-08-13
Journal: Scientific Reports [Category] MERS, 신약개발, 임상, 진단, 치료법, 치료제,

[키워드] addition Anosmia Azithromycin biochemical evaluation blood count C-reactive protein CBC Chain Reaction Chest computed tomography Chest CT clarithromycin complete blood count Computed tomography control group cough COVID-19 CRP D-dimer Dyspnea Efficacy Fever gastrointestinal tract management Mild Molecular biology Molecular medicine Negative conversion no significant difference Patient patients treated patients with COVID-19 PCR performed polymerase chain reaction protocol randomized trial real-time reverse transcription-polymerase chain reaction regimen Registered rRT-PCR SARS-CoV-2 PCR Serum ferritin significant difference standard care Standard of care study participant Study participants supportive care Symptom Symptomatic treatment therapeutic three group three groups Treatment treatment regimen Trial registration
[DOI] 10.1038/s41598-021-95900-z PMC 바로가기 [Article Type] Randomized Controlled Trial